Equities Analysts Offer Predictions for ACHV FY2025 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Investment analysts at HC Wainwright lowered their FY2025 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on Thursday, November 6th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will earn ($1.29) per share for the year, down from their previous forecast of ($1.13). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q4 2025 earnings at ($0.30) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at $0.45 EPS and FY2029 earnings at $1.16 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Achieve Life Sciences Trading Down 3.2%

Shares of ACHV opened at $4.59 on Monday. Achieve Life Sciences has a 1-year low of $1.84 and a 1-year high of $5.78. The company has a 50-day moving average of $3.65 and a 200 day moving average of $3.13. The firm has a market capitalization of $234.57 million, a price-to-earnings ratio of -3.14 and a beta of 1.62. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.64 and a quick ratio of 6.64.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Insider Buying and Selling

In other news, Director Thomas Braxton King sold 139,858 shares of Achieve Life Sciences stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $2.77, for a total value of $387,406.66. Following the transaction, the director directly owned 315,142 shares in the company, valued at approximately $872,943.34. This trade represents a 30.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jaime Xinos sold 20,854 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $2.77, for a total value of $57,765.58. Following the completion of the transaction, the insider directly owned 74,432 shares of the company’s stock, valued at approximately $206,176.64. The trade was a 21.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 381,972 shares of company stock valued at $1,084,997 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Achieve Life Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC boosted its holdings in shares of Achieve Life Sciences by 37.4% in the 1st quarter. Nantahala Capital Management LLC now owns 898,885 shares of the biopharmaceutical company’s stock valued at $2,400,000 after buying an additional 244,885 shares in the last quarter. Manchester Financial Inc. raised its stake in shares of Achieve Life Sciences by 90.8% during the 2nd quarter. Manchester Financial Inc. now owns 46,224 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 22,000 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Achieve Life Sciences during the 1st quarter worth approximately $99,000. Nuveen LLC purchased a new stake in Achieve Life Sciences during the first quarter valued at approximately $125,000. Finally, Invesco Ltd. boosted its stake in Achieve Life Sciences by 338.7% in the first quarter. Invesco Ltd. now owns 73,644 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 56,856 shares in the last quarter. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.